Validea Detailed Fundamental Analysis

Validea's Multi-Factor Investor model, based on Pim van Vliet's low-volatility strategy, rated Elevance Health (ELV) at 68%, falling below the 80% threshold for 'some interest.' While ELV passed market capitalization and standard deviation criteria, it registered 'NEUTRAL' for twelve-month momentum and net payout yield, resulting in an overall 'FAIL' in the final rank. This indicates ELV does not currently align with the specific low-volatility, momentum, and net payout yield characteristics sought by this quantitative model.

Analysis

Elevance Health (ELV) received a score of 68% from Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy prioritizing low volatility, strong momentum, and high net payout yield. This score falls below the 80% threshold that typically indicates strategic interest. While ELV, a large-cap growth stock in the health insurance sector, successfully passed the model's criteria for market capitalization and low volatility (Standard Deviation), it only achieved a 'NEUTRAL' rating on two other key factors: 'Twelve Minus One Momentum' and 'Net Payout Yield'. The combination of these neutral factors, despite the favorable low-risk profile, led to an overall 'FAIL' on the model's final rank. This quantitative assessment, reflected in the moderately negative sentiment score of -0.4 for the ticker, suggests that ELV's current profile does not align with the specific combination of factors sought by this particular low-risk, high-return investment strategy.

Key Decisions for Investors

• Investors employing factor-based strategies, specifically those aligned with Pim van Vliet's model, should note that ELV currently fails to meet the required criteria due to weaknesses in momentum and net payout yield.
• While the stock's low-volatility characteristic is confirmed by the model, those seeking near-term alpha from momentum or high shareholder returns may find ELV's current profile suboptimal.
• Consider monitoring ELV's capital return policies and price momentum, as an improvement in its net payout yield or a strengthening of its twelve-month momentum would be necessary for it to become favorable under this quantitative screen.